Nils Eckardt, Chief Medical Affairs Officer at Agenus and Vice President of Academic and Strategic Partnerships (GMA ex-China) at BeiGene, shared a post on LinkedIn by Jean-Charles Soria, Senior Vice President and Oncology Therapeutic Area Head at Amgen, adding:
“Understanding established targets in tumor biology drives the design of new treatments for hot and cold tumors with an improved tolerability profile such as botensilimab.”
Quoting Jean-Charles Soria’s post:
“FcγR engagement influences antibody efficacy, toxicity, and pharmacokinetics:
Effector Functions: Critical for anti-CTLA4 to deplete Tregs via ADCC/ADCP; unnecessary for anti-PD(L)1.
Toxicity: Increases immune-related adverse events (irAEs) and infusion reactions.
Pharmacokinetics: FcγR engagement influences antibody clearance and shortens half-life.
Hyperprogression: FcγRIIb engagement may trigger immunosuppression or PD-1+ T-cell depletion.
Polymorphisms: FcγR variants affect efficacy Immunotherapy.”
“Fc Effector Function of Immune Checkpoint Blocking Antibodies in Oncology“
Authors: Romane Martineau, Sandrine Susini and Aurelien Marabelle
Jean-Charles Soria serves as Amgen’s senior vice president of Oncology within Global Development. He is a medical oncologist and a professor of medicine at Paris-Saclay University. From 2017 to 2019, he was the senior vice president of Research and Development in Oncology at AstraZeneca. Additionally, Soria has authored or co-authored over 670 articles in leading international journals and has been recognized as one of the world’s most influential research scientists.
For more updates, follow OncoDaily.